BE

BioTelemetry

- NASDAQ:BEAT
Last Updated 2024-04-19

Indeed Snapshot

Track BioTelemetry reviews on Indeed to uncover insights on employee sentiment

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Profile Url Name Website Industry Description Revenue Headquarters location CEO Rating: CEO (%) Rating: CEO Responses Count Rating: Overall Happiness: Compensation score Happiness: Support score Happiness: Purpose score Happiness: Flexibility score Happiness: Energy score Happiness: Work Happiness score Happiness: Trust score Happiness: Learning score Happiness: Belonging score Happiness: Inclusion score Happiness: Overall score Happiness: Appreciation score Happiness: Achievement score Happiness: Responses Count Review Count Ratings Responses Count Rating: Culture & Values Rating: Compensation & Benefits Rating: Job Security & Advancement Rating: Senior Management Rating: Worklife Balance Interview: Duration Responses count Interview Duration Interview: Difficulty Responses count Interview Difficulty Interview: Experience Responses count Interview Experience Work Culture: Stressful (0) to Relaxed (1) Ratio Work Culture: Slow Paced (0) to Fast Paced (1) Ratio Work Culture: Competitive (0) to Collaborative (1) Ratio Date Added Date Updated Company Name Sector Industry
nasdaq:beat https://www.indeed.com/cmp/biotelemetry Aug 29th, 2022 12:00AM Open BioTelemetry Pharmaceutical & Biotechnology RRv1_100M_500M Malvern, PA 2.70 56.0 60.0 63.0 62.0 52.0 54.0 51.0 57.0 49.0 55.0 54.0 60.0 61.0 85.0 118.00 118.00 2.60 2.80 2.50 2.30 2.80 40.00 About a week 46.00 EASY 44.00 AVERAGE Aug 29th, 2022 11:32AM Aug 29th, 2022 11:32AM BioTelemetry Health Care Health Care Equipment & Services
nasdaq:beat https://www.indeed.com/cmp/cardionet Aug 29th, 2022 12:00AM Open CardioNet Healthcare CardioNet wants to be as close as your next heartbeat. The company provides real-time outpatient cardiac monitoring and telemetry services for ambulatory (mobile) patients throughout the US. By providing continuous heartbeat monitoring with nearly three weeks of data, the CardioNet System provides doctors with a complete picture of heart functions to help diagnose and monitor arrhythmias (abnormal heart rhythms). The system relies on two-way wireless communication -- providing mobility for the patient and remote adjustment for physicians. CardioNet also manufactures and sells traditional cardiac event and Holter monitors, which record patient heart rhythm data, but cannot transmit the data in real time. CardioNet's Mobile Cardiac Outpatient Telemetry (MCOT) services rely on the system's FDA-approved monitoring equipment, wireless transmission network, proprietary software, and a 24-hour monitoring center. The MCOT system automatically detects rhythm irregularities and transmits the corresponding ECG (electrocardiogram) data to the monitoring center. The CardioNet System is marketed directly to doctors and patients throughout the US and has been used with more than 500,000 patients. While Medicare reimbursements account for a third of the company's revenues, it also has contracts with more than 350 commercial payers. Part of CardioNet's strategy is to increase the number of (more lucrative) commercial payer contracts it has as compared to its government contracts. CardioNet's revenues climbed up to $140.6 million in 2009, but that year Medicare sharply reduced the rate it reimburses for for MCOT services and the commercial insurance carries followed suit. Additionally, some large commercial health plans have deemed the services to be experimental and do not reimburse for them at all. These factors have bit hard: in 2010 patient service revenues dropped 15% to $119.9 million, and then dropped an additional 11% in 2011 down to 106.8 million. However, as a result of its 2010 acquisition of Biotel, the company added product manufacturing which has offset losses in patient services. Product manufacturing, repair, and sales added revenue of some $12.2 million in 2011. CardioNet's revenues are likely to wobble for a while. Shifting to event and Holter monitoring may boost its patient volume, but such monitoring is reimbursed at a lower rate. Acquisitions have helped CardioNet with its expansion of products, services, and geographic range. The company intends to move beyond arrhythmia monitoring into new market areas such as cardiac monitoring for clinical trials and disease management for congestive heart failure, diabetes, and other diseases that require outpatient or ambulatory monitoring and management. To that end, in 2012 it paid some $23.5 million to acquire CardioCORE Lab. That business gives CardioNet centralized cardiac testing labs in the US and UK. CardioNet has plans to use its technology to create instant telemetry beds (which allow patients to be continually monitored by technology) in rural hospitals, step-down units, or skilled nursing facilities to help cope with acute nursing shortages by reducing the number of nurses needed to oversee ECG monitoring and reduce capital equipment costs. Proceeds from CardioNet's 2007 IPO were used to pay off debt, bankroll acquisitions, build up inventory of CardioNet systems, and develop improved versions of the product. RRv1_100M_500M 227 Washington St. Ste. 300 Conshohocken PA, United States 19428 3.50 70.00 70.00 3.40 3.70 3.00 3.00 3.40 5.00 MEDIUM 5.00 AVERAGE Aug 29th, 2022 11:32AM Aug 29th, 2022 11:32AM BioTelemetry Health Care Health Care Equipment & Services
nasdaq:beat https://www.indeed.com/cmp/lifewatch Aug 29th, 2022 12:00AM Open LifeWatch Medical Testing & Clinical Laboratories 3.60 39.00 39.00 3.20 3.50 3.00 3.30 3.70 8.00 About a day or two 10.00 MEDIUM 10.00 FAVORABLE Aug 29th, 2022 11:32AM Aug 29th, 2022 11:32AM BioTelemetry Health Care Health Care Equipment & Services
nasdaq:beat https://www.indeed.com/cmp/cardionet Aug 28th, 2022 12:00AM Open CardioNet Healthcare CardioNet wants to be as close as your next heartbeat. The company provides real-time outpatient cardiac monitoring and telemetry services for ambulatory (mobile) patients throughout the US. By providing continuous heartbeat monitoring with nearly three weeks of data, the CardioNet System provides doctors with a complete picture of heart functions to help diagnose and monitor arrhythmias (abnormal heart rhythms). The system relies on two-way wireless communication -- providing mobility for the patient and remote adjustment for physicians. CardioNet also manufactures and sells traditional cardiac event and Holter monitors, which record patient heart rhythm data, but cannot transmit the data in real time. CardioNet's Mobile Cardiac Outpatient Telemetry (MCOT) services rely on the system's FDA-approved monitoring equipment, wireless transmission network, proprietary software, and a 24-hour monitoring center. The MCOT system automatically detects rhythm irregularities and transmits the corresponding ECG (electrocardiogram) data to the monitoring center. The CardioNet System is marketed directly to doctors and patients throughout the US and has been used with more than 500,000 patients. While Medicare reimbursements account for a third of the company's revenues, it also has contracts with more than 350 commercial payers. Part of CardioNet's strategy is to increase the number of (more lucrative) commercial payer contracts it has as compared to its government contracts. CardioNet's revenues climbed up to $140.6 million in 2009, but that year Medicare sharply reduced the rate it reimburses for for MCOT services and the commercial insurance carries followed suit. Additionally, some large commercial health plans have deemed the services to be experimental and do not reimburse for them at all. These factors have bit hard: in 2010 patient service revenues dropped 15% to $119.9 million, and then dropped an additional 11% in 2011 down to 106.8 million. However, as a result of its 2010 acquisition of Biotel, the company added product manufacturing which has offset losses in patient services. Product manufacturing, repair, and sales added revenue of some $12.2 million in 2011. CardioNet's revenues are likely to wobble for a while. Shifting to event and Holter monitoring may boost its patient volume, but such monitoring is reimbursed at a lower rate. Acquisitions have helped CardioNet with its expansion of products, services, and geographic range. The company intends to move beyond arrhythmia monitoring into new market areas such as cardiac monitoring for clinical trials and disease management for congestive heart failure, diabetes, and other diseases that require outpatient or ambulatory monitoring and management. To that end, in 2012 it paid some $23.5 million to acquire CardioCORE Lab. That business gives CardioNet centralized cardiac testing labs in the US and UK. CardioNet has plans to use its technology to create instant telemetry beds (which allow patients to be continually monitored by technology) in rural hospitals, step-down units, or skilled nursing facilities to help cope with acute nursing shortages by reducing the number of nurses needed to oversee ECG monitoring and reduce capital equipment costs. Proceeds from CardioNet's 2007 IPO were used to pay off debt, bankroll acquisitions, build up inventory of CardioNet systems, and develop improved versions of the product. RRv1_100M_500M 227 Washington St. Ste. 300 Conshohocken PA, United States 19428 3.50 70.00 70.00 3.40 3.70 3.00 3.00 3.40 5.00 MEDIUM 5.00 AVERAGE Aug 28th, 2022 04:31AM Aug 28th, 2022 04:31AM BioTelemetry Health Care Health Care Equipment & Services
nasdaq:beat https://www.indeed.com/cmp/biotelemetry Aug 28th, 2022 12:00AM Open BioTelemetry Pharmaceutical & Biotechnology RRv1_100M_500M Malvern, PA 2.70 56.0 60.0 63.0 62.0 52.0 54.0 51.0 57.0 49.0 55.0 54.0 60.0 61.0 85.0 118.00 118.00 2.60 2.80 2.50 2.30 2.80 40.00 About a week 46.00 EASY 44.00 AVERAGE Aug 28th, 2022 04:31AM Aug 28th, 2022 04:31AM BioTelemetry Health Care Health Care Equipment & Services
nasdaq:beat https://www.indeed.com/cmp/lifewatch Aug 28th, 2022 12:00AM Open LifeWatch Medical Testing & Clinical Laboratories 3.60 39.00 39.00 3.20 3.50 3.00 3.30 3.70 8.00 About a day or two 10.00 MEDIUM 10.00 FAVORABLE Aug 28th, 2022 04:31AM Aug 28th, 2022 04:31AM BioTelemetry Health Care Health Care Equipment & Services
nasdaq:beat https://www.indeed.com/cmp/lifewatch Aug 27th, 2022 12:00AM Open LifeWatch Medical Testing & Clinical Laboratories 3.60 39.00 39.00 3.20 3.50 3.00 3.30 3.70 8.00 About a day or two 10.00 MEDIUM 10.00 FAVORABLE Aug 27th, 2022 03:51AM Aug 27th, 2022 03:51AM BioTelemetry Health Care Health Care Equipment & Services
nasdaq:beat https://www.indeed.com/cmp/biotelemetry Aug 27th, 2022 12:00AM Open BioTelemetry Pharmaceutical & Biotechnology RRv1_100M_500M Malvern, PA 2.70 56.0 60.0 63.0 62.0 52.0 54.0 51.0 57.0 49.0 55.0 54.0 60.0 61.0 85.0 117.00 117.00 2.60 2.80 2.50 2.30 2.80 40.00 About a week 46.00 EASY 44.00 AVERAGE Aug 27th, 2022 03:51AM Aug 27th, 2022 03:51AM BioTelemetry Health Care Health Care Equipment & Services
nasdaq:beat https://www.indeed.com/cmp/cardionet Aug 27th, 2022 12:00AM Open CardioNet Healthcare CardioNet wants to be as close as your next heartbeat. The company provides real-time outpatient cardiac monitoring and telemetry services for ambulatory (mobile) patients throughout the US. By providing continuous heartbeat monitoring with nearly three weeks of data, the CardioNet System provides doctors with a complete picture of heart functions to help diagnose and monitor arrhythmias (abnormal heart rhythms). The system relies on two-way wireless communication -- providing mobility for the patient and remote adjustment for physicians. CardioNet also manufactures and sells traditional cardiac event and Holter monitors, which record patient heart rhythm data, but cannot transmit the data in real time. CardioNet's Mobile Cardiac Outpatient Telemetry (MCOT) services rely on the system's FDA-approved monitoring equipment, wireless transmission network, proprietary software, and a 24-hour monitoring center. The MCOT system automatically detects rhythm irregularities and transmits the corresponding ECG (electrocardiogram) data to the monitoring center. The CardioNet System is marketed directly to doctors and patients throughout the US and has been used with more than 500,000 patients. While Medicare reimbursements account for a third of the company's revenues, it also has contracts with more than 350 commercial payers. Part of CardioNet's strategy is to increase the number of (more lucrative) commercial payer contracts it has as compared to its government contracts. CardioNet's revenues climbed up to $140.6 million in 2009, but that year Medicare sharply reduced the rate it reimburses for for MCOT services and the commercial insurance carries followed suit. Additionally, some large commercial health plans have deemed the services to be experimental and do not reimburse for them at all. These factors have bit hard: in 2010 patient service revenues dropped 15% to $119.9 million, and then dropped an additional 11% in 2011 down to 106.8 million. However, as a result of its 2010 acquisition of Biotel, the company added product manufacturing which has offset losses in patient services. Product manufacturing, repair, and sales added revenue of some $12.2 million in 2011. CardioNet's revenues are likely to wobble for a while. Shifting to event and Holter monitoring may boost its patient volume, but such monitoring is reimbursed at a lower rate. Acquisitions have helped CardioNet with its expansion of products, services, and geographic range. The company intends to move beyond arrhythmia monitoring into new market areas such as cardiac monitoring for clinical trials and disease management for congestive heart failure, diabetes, and other diseases that require outpatient or ambulatory monitoring and management. To that end, in 2012 it paid some $23.5 million to acquire CardioCORE Lab. That business gives CardioNet centralized cardiac testing labs in the US and UK. CardioNet has plans to use its technology to create instant telemetry beds (which allow patients to be continually monitored by technology) in rural hospitals, step-down units, or skilled nursing facilities to help cope with acute nursing shortages by reducing the number of nurses needed to oversee ECG monitoring and reduce capital equipment costs. Proceeds from CardioNet's 2007 IPO were used to pay off debt, bankroll acquisitions, build up inventory of CardioNet systems, and develop improved versions of the product. RRv1_100M_500M 227 Washington St. Ste. 300 Conshohocken PA, United States 19428 3.50 70.00 70.00 3.40 3.70 3.00 3.00 3.40 5.00 MEDIUM 5.00 AVERAGE Aug 27th, 2022 03:51AM Aug 27th, 2022 03:51AM BioTelemetry Health Care Health Care Equipment & Services
nasdaq:beat https://www.indeed.com/cmp/biotelemetry Aug 25th, 2022 12:00AM Open BioTelemetry Pharmaceutical & Biotechnology RRv1_100M_500M Malvern, PA 2.70 56.0 60.0 63.0 62.0 52.0 54.0 51.0 57.0 49.0 55.0 54.0 60.0 61.0 85.0 116.00 116.00 2.60 2.80 2.50 2.30 2.80 39.00 About a week 45.00 EASY 44.00 AVERAGE Aug 25th, 2022 08:30AM Aug 25th, 2022 08:30AM BioTelemetry Health Care Health Care Equipment & Services

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.